Longevity Acquisition announced today that its shareholders unanimously approved the SPAC’s merger with 4d pharma.
Under terms of the deal announced in October, 4D pharma would receive the $14.6 million cash held by Longevity in trust. In addition, 4D pharma would gain the proceeds of warrants to purchase Longevity shares worth up to $23 million. Read more.
